Clinical Trial Update: Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with TCb versus TCb alone as neoadjuvant therapy for triple-negative breast cancer. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhenzhen Liu | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING